ClinicalTrials.gg
RecruitingNCT07792980AI-MPRO3Updated Aug 28, 2026

AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients

An interventional study of Placebo and MPRO3 in Colon Neoplasms, sponsored by hy Co., LTD.. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by hy Co., LTD. · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Colonic Neoplasms with a site in Korea, Republic of — 13 open to participants now, 29 under way, 10 of them phase 3. Colonic Neoplasms · Korea, Republic of.

Planned enrollment
44th of 65
100 · median 174
Started
2026
with 1 other
No phase
23 of 82
4 open now
Primary completion
2028-04
later than 21 of 28 live
Registered
82nd of 82
by date

Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, this one is the 44th largest by planned enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 82nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

13 of the 82 studies in Colonic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Colonic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.

03

Conditions studied

  • Colon Neoplasms

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A person who is diagnosed histologically or radiologically with adenocarcinoma of the colon and is scheduled to undergo surgery

Exclusion criteria

Exclusion Criteria:

  • A person who has received chemotherapy or radiotherapy for colon cancer before surgery
  • A person with fecal incontinence
  • A person who has been diagnosed with an acute or serious disease, such as liver, kidney, heart, or thyroid disease, or is taking related medication
  • A person with alcohol dependence or a history of drug abuse
  • A person with immune system disorders, infectious diseases, or gastrointestinal diseases, including inflammatory bowel disease
  • A person who is currently diagnosed with or receiving treatment for another type of cancer
  • A person with renal dysfunction, defined as serum creatinine at least 1.5 times the , or liver dysfunction, defined as and/or ALT at least 2.5 times the upper limit of normal
  • A person who has continuously used probiotics within the previous week
  • A person who is pregnant or lactating
  • A person who has to the product or any of its ingredients, or an allergy to a specific ingredient
  • A person who has participated in another human study or drug clinical trial within one month before the start of this study, except for a study involving only non-invasive surveys
  • A person who is unable to read letters or whose ability is limited
  • A person deemed inappropriate by the investigator to participate in this study for other reasons
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo is a matching formulation that does not contain the three probiotic strains included in MPR03.

    Dietary Supplement: Placebo

  • Experimental
    MPRO3

    MPR03 is a probiotic formulation containing a mixture of three probiotic strains: Bifidobacterium animalis subsp. lactis HY8002, Lacticaseibacillus paracasei HY2782, and Lactiplantibacillus plantarum HY7712.

    Dietary Supplement: MPRO3

Interventions

  • Dietary supplementPlacebo

    Participants will receive one placebo capsule orally once daily after breakfast for 13 weeks.

  • Dietary supplementMPRO3

    Participants will receive one MPRO3 capsule orally once daily after breakfast for 13 weeks.

06

What researchers measure

Primary outcomes

  1. Postoperative Infectious Complications (Infectious complications)

    The occurrence of postoperative infectious complications is assessed according to the CDC/NHSN criteria.

    Time frame: 4 weeks after surgery, 12 weeks after surgery

Secondary outcomes

  1. Comprehensive Complication Index

    Postoperative complications are graded according to the Clavien-Dindo classification and summarized as a Comprehensive Complication Index score ranging from 0 to 100.

    Time frame: 4 weeks after surgery, 12 weeks after surgery

  2. Postoperative Length of Hospital Stay (LOS)

    Postoperative length of hospital stay is calculated from the date of surgery to hospital discharge based on medical records.

    Time frame: 4 weeks after surgery

  3. Inflammation-related Marker 1: Glasgow prognostic score (GPS)

    The Glasgow Prognostic Score (GPS) is assessed using inflammatory markers measured in venous blood and is calculated based on serum albumin and high-sensitivity C-reactive protein (HS-CRP) levels. The total score ranges from 0 to 2. A score of 0 is assigned when HS-CRP is ≤10 mg/L and albumin is ≥35 g/L. A score of 1 is assigned when either HS-CRP is \>10 mg/L or albumin is \<35 g/L. A score of 2 is assigned when HS-CRP is \>10 mg/L and albumin is \<35 g/L. Higher scores indicate a worse prognostic status.

    Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery

  4. Inflammation-related Markers 2: White Blood Cell (WBC), C-reactive protein (CRP), Neutrophils, lymphocytes, Monocytes, Platelets (PLT), neutrophil-to-lymphocyte ratio (NLR)

    Inflammation-related markers are assessed using venous blood samples. WBC and Platelets (PLT) are measured in 10\^9/L. Neutrophils, lymphocytes, and Monocytes are reported as percentages (%). CRP is measured in mg/dL. The neutrophil-to-lymphocyte ratio (NLR) is reported as a unitless ratio.

    Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery

  5. Inflammation Markers 3: Procalcitonin, Blood Culture (BC), Serum Amyloid A (SAA), Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17)

    Procalcitonin, BC, SAA, Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17) are assessed using venous blood samples. Procalcitonin is measured in ng/mL, SAA in mg/L, and Zonulin in ng/mL. BC is recorded as a qualitative result (Positive/Negative). Cytokines assessed include TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, and IL-17, measured in pg/mL.

    Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery

  6. Immune-related Markers 1: Natural Killer cell cytotoxicity (NK cytotoxicity), Natural Killer cell subset (NK subset)

    Immune-related markers are assessed using venous blood samples. NK cytotoxicity and NK subset are reported as percentages (%).

    Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery

  7. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) is used to assess quality of life in patients with cancer. It consists of three domains: global health status/quality of life, functional, and symptom domains, with a total of 30 items. Scores are transformed to a scale ranging from 0 to 100 according to the EORTC QLQ-C30 scoring manual. Higher scores for global health status/quality of life and the functional domain indicate better quality of life, whereas higher scores for the symptom domain indicate worse quality of life.

    Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery

  8. Bowel Function Assessment 1: Bowel Diary

    As part of the bowel function assessment, a bowel diary is used to record the frequency and form of bowel movements.

    Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery

  9. Bowel Function Assessment 2: Postoperative Bowel Function Questionnaire

    As part of the bowel function assessment, the Postoperative Bowel Function Questionnaire is used to assess postoperative bowel function and recovery, including time to first passage of flatus, time to first bowel movement, and other related measures.

    Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery

  10. Nutritional Status Assessment 1: Patient-Generated Subjective Global Assessment (PG-SGA)

    As part of the nutritional status assessment, the Patient-Generated Subjective Global Assessment (PG-SGA) is used to evaluate nutritional status based on factors including changes in body weight and dietary intake, gastrointestinal symptoms affecting food intake, physical examination findings, and comorbidities.

    Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery

  11. Nutritional Status Assessment 2: Prognostic Nutritional Index (PNI)

    As part of the nutritional status assessment, the Prognostic Nutritional Index (PNI) is calculated based on Serum Albumin and Total Lymphocyte Count. PNI is calculated as 10 × Serum Albumin (g/dL) + 0.005 × Total Lymphocyte Count (/mm³).

    Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery

Other outcomes

  1. Fecal Microbiome (16S/Shotgun, NGS, SCFA)

    Fecal collection kits are sent to participants, who are instructed to collect stool samples at home within 2 days of each visit. The collected samples are placed in the designated kits and returned by courier to the analytical laboratory.

    Time frame: 1 week before surgery, 4 weeks, 12 weeks after surgery

  2. Tumor Transcriptome (RNA-seq)

    Normal tissue and tumor tissue are collected during surgery.

    Time frame: During surgery

  3. Adaptive immunity test (T cell exhaustion marker, CEA/NY-ESO-1/ST4-specific T cell)

    Adaptive immunity is assessed using T-cell exhaustion markers and CEA/NY-ESO-1/ST4-specific T-cell responses. These measurements are used to analyze the association between changes in immune status before and after surgery and clinical prognosis, and to evaluate changes in immune response following probiotic intake.

    Time frame: Baseline, 4 weeks, 12 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Apr 2028, 20 months after the start.

Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 28, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Apr 12, 2028
CompletionEst.
Apr 12, 2028
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07792980
Lead sponsor
hy Co., LTD.
Collaborators
Nutriworks, ImmunoBiome
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Aug 4, 2026
Primary completion
Apr 12, 2028 (estimated)
Completion
Apr 12, 2028 (estimated)
Last update
Aug 28, 2026

Study contacts

Nayeon Song
Contact
mind1088@naver.com
+82-10-4365-1088

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion